Grant: Engage Grants Program
Université du Québec à Montréal
$25,000.00
Synthesis of new compounds targeting bacterial pyruvate kinase
FY 2009-10
Summary
Indel Therapeutics Inc. is a company focused on the discovery and development of new antimicrobial agents.
The company is working to establish a collaborative agreement with the department of chemistry at the
University of Quebec in Montreal.
The company has recently discovered pyruvate kinase as a new antibacterial target and has a lead molecule that
is in need of exploratory medicinal chemistry. The objective of the program is to prepare a number of
divergent molecules to identify the most appropriate follow on lead series.
The laboratory of Professor René Roy is well renowned in the type of chemistry that Indel requires and will be
responsible for the synthesis of the new molecules. Indel Therapeutics will then test the new compounds and
provide feedback in order to establish a productive research collaboration that will hopefully lead to a
long-term relationship between the two groups.
Program
Engage Grants Program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
395924-2009
Name nom
Roy, René
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
1
Application title
Synthesis of new compounds targeting bacterial pyruvate kinase
Keyword
NA
Application summary
Indel Therapeutics Inc. is a company focused on the discovery and development of new antimicrobial agents.
The company is working to establish a collaborative agreement with the department of chemistry at the
University of Quebec in Montreal.
The company has recently discovered pyruvate kinase as a new antibacterial target and has a lead molecule that
is in need of exploratory medicinal chemistry. The objective of the program is to prepare a number of
divergent molecules to identify the most appropriate follow on lead series.
The laboratory of Professor René Roy is well renowned in the type of chemistry that Indel requires and will be
responsible for the synthesis of the new molecules. Indel Therapeutics will then test the new compounds and
provide feedback in order to establish a productive research collaboration that will hopefully lead to a
long-term relationship between the two groups.